Skip to content
OpenCapital
Get started

Lantheus Holdings LNTH Cash & Equivalents

Cash & Equivalents at other companies

Guardant Health logo
Guardant HealthGH
$1.1B+37.0%
Revvity logo
RevvityRVTY
$861.47M-24.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$205.19M+238%
Labcorp Holdings logo
Labcorp HoldingsLH
$981.1M+166%
Agilent Technologies logo
Agilent TechnologiesA
$1.81B+21.5%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
——

Other financials

Income statement

See full
Revenue$377.3M+1.2%
Gross profit$230.9M-2.9%
Operating income$81.3M-20.3%
Net income$118.4M+62.3%
EPS (diluted)$1.80+76.5%

Balance sheet

See full
Total debt$627.9M+1.8%
Total equity$1.2B+4.1%
Total assets$2.3B+14.2%

Cash flow

See full
Operating cash flow$125.1M+16.3%
CapEx$3.2M-63.0%
Free cash flow$121.9M+23.3%

Valuation

See full
Market cap$6.76B-26.3%
Enterprise value$6.89B-20.5%
P/E24.2×-10.2×
P/S4.4×-1.6×

Profitability

See full
Gross margin60.5%-3.6pp
Operating margin18.8%-10.7pp
Net margin18%+0.7pp
FCF margin24.4%-6.4pp

Returns & leverage

See full
Return on equity23.5%-1.7pp
Debt / equity0.5×0.0×
Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Lantheus Holdings’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lantheus Holdings's cash & equivalents?
Lantheus Holdings (LNTH) reported cash & equivalents of $500.29M in Q1 2026.
How has Lantheus Holdings's cash & equivalents changed year-over-year?
Lantheus Holdings's cash & equivalents decreased by 46.8% year-over-year, from $940.21M to $500.29M.
What is the long-term trend for Lantheus Holdings's cash & equivalents?
Over 5 years (2020 to 2025), Lantheus Holdings's cash & equivalents has grown at a 34.3% compound annual growth rate (CAGR), from $82.69M to $360.83M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.